Merck

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Merck 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About MRK

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. 

CEO
Robert M. Davis
CEORobert M. Davis
Employees
75,000
Employees75,000
Headquarters
Rahway, New Jersey
HeadquartersRahway, New Jersey
Founded
1891
Founded1891
Employees
75,000
Employees75,000

MRK Key Statistics

Market cap
366.55B
Market cap366.55B
Price-Earnings ratio
120.16
Price-Earnings ratio120.16
Dividend yield
2.24%
Dividend yield2.24%
Average volume
9.51M
Average volume9.51M
High today
$149.59
High today$149.59
Low today
$146.28
Low today$146.28
Open price
$148.27
Open price$148.27
Volume
3.02M
Volume3.02M
52 Week high
$156.92
52 Week high$156.92
52 Week low
$77.58
52 Week low$77.58

Stock Snapshot

Merck(MRK) stock is priced at $148.57, giving the company a market capitalization of 366.55B. It carries a P/E multiple of 120.16 and pays a dividend yield of 2.24%.

On 2026-09-08, Merck(MRK) stock moved within a range of $146.28 to $149.59. With shares now at $148.57, the stock is trading +1.6% above its intraday low and -0.7% below the session's peak.

Trading volume for Merck(MRK) stock has reached 3.02M, versus its average volume of 9.51M.

The stock's 52-week range extends from a low of $77.58 to a high of $156.92.

The stock's 52-week range extends from a low of $77.58 to a high of $156.92.

MRK News

Investing.com 6h
Guggenheim raises Merck stock price target to $170 on cancer drug - Investing.com

...

Guggenheim raises Merck stock price target to $170 on cancer drug - Investing.com
TipRanks 6h
Merck price target raised to $170 from $146 at Guggenheim

Guggenheim raised the firm’s price target on Merck (MRK) to $170 from $146 and keeps a Buy rating on the shares, driven mainly by increased sales estimates for...

Simply Wall St 4d
Merck, Why Is Its Latest Update Raising Bigger Questions?

Merck (MRK) is in focus after the FDA approved LIPFENDRA, the first oral PCSK9 inhibitor for hypercholesterolemia, while competitive pressure builds around its...

Merck, Why Is Its Latest Update Raising Bigger Questions?

Analyst ratings

68%

of 31 ratings
Buy
67.7%
Hold
29%
Sell
3.2%

More MRK News

Simply Wall St 5d
Merck Stock Could Trade Below Fair Value Despite Rich Earnings

Merck stock has surged over recent years, yet the valuation signals are mixed, with a Discounted Cash Flow (DCF) intrinsic value estimate pointing to undervalua...

Merck Stock Could Trade Below Fair Value Despite Rich Earnings
TipRanks 6d
H.C. Wainwright views Novartis, Alteogen pact as negative for Halozyme

H.C. Wainwright reiterates a Buy rating on Halozyme (HALO) with a $115 price target after Novartis (NVS) signed an option and license agreement with Alteogen co...

People also own

Based on the portfolios of people who own MRK. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.